News from calliditas therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

03 Jul, 2019, 07:10 BST Calliditas has Resolved on a Directed Share Issue in the Amount of 3.5 Million Shares, Raising Proceeds of Approximately SEK 210 Million

Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company"), a specialty pharmaceutical company focused on the development of high quality...


02 Jul, 2019, 17:33 BST Calliditas Considers a Directed Share Issue

Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company"), a specialty pharmaceutical company focused on the development of high quality...


10 Jun, 2019, 07:19 BST Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Calliditas Therapeutics AB ("Calliditas") and Everest Medicines II Limited ("Everest Medicines") announced today that they have entered into a...


04 Jun, 2019, 12:26 BST Calliditas Therapeutics to Present at Redeye Growth Day

Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the company will present at Redeye Growth Day on Monday,...


08 May, 2019, 06:20 BST Calliditas Therapeutics: Interim Report Q1, 2019

"This first quarter of 2019, we were busy ensuring that the recruitment efforts for our pivotal phase 3 study NefIgArd remain on track, focusing on...


06 May, 2019, 14:09 BST Calliditas Therapeutics to Host Conference Call to Provide Business Update and 2019 Q1 Report

On May 8, 2019, at 07:00am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the first quarter 2019. The company will...


05 Apr, 2019, 10:49 BST Elmar Schnee and Diane Parks Proposed as New Board Members of Calliditas Therapeutics

The nomination committee of Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) ("Calliditas") has proposed that Elmar Schnee and Diane Parks be...


03 Apr, 2019, 12:39 BST Calliditas Therapeutics to Present at the Needham Healthcare Conference

Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that Renée Aguiar-Lucander, the company's Chief Executive...


04 Mar, 2019, 09:23 GMT Calliditas Therapeutics to Present at March Investor Conferences

Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) today announced that senior management will present at the following upcoming investor...


12 Feb, 2019, 10:48 GMT Calliditas Therapeutics Granted Orphan Drug Designation by the FDA for Primary Biliary Cholangitis

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation...


07 Feb, 2019, 06:22 GMT Calliditas Therapeutics - Year-end report, 2018

"2018 was an exciting and transformational year for Calliditas. We listed on Nasdaq Stockholm and raised sufficient capital to fund our pivotal...


05 Feb, 2019, 09:36 GMT Therapeutics Granted Orphan Drug Designation by the FDA for Autoimmune Hepatitis

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation...


01 Feb, 2019, 09:35 GMT Calliditas Therapeutics to Host Conference Call to Provide Business Update and 2018 Full-year Report

On February 7, 2019, at 07:00am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the full-year 2018. The company will ...


14 Jan, 2019, 13:40 GMT Calliditas Therapeutics Appoints Frank Bringstrup as VP Regulatory Affairs

Calliditas Therapeutics AB (publ) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced the appointment of Dr. Frank Bringstrup as Vice President...


08 Jan, 2019, 06:27 GMT Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America

Calliditas Therapeutics AB (publ) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced the appointment of Andrew Udell as Vice President, North...


13 Nov, 2018, 15:29 GMT First patient Enrolled in Pivotal Clinical Phase 3 Study NEFIGARD with Lead Candidate Nefecon

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the first patient has been enrolled in the company's pivotal clinical phase 3...


09 Nov, 2018, 13:20 GMT Calliditas Therapeutics to Present and Attend Investor Conferences in November 2018

Stifel 2018 Healthcare Conference Calliditas Therapeutics AB (publ) today announced that management will present at the Stifel 2018 Healthcare...


01 Nov, 2018, 09:54 GMT Calliditas Therapeutics - Interim Report Q3, 2018

NefIgArd Phase 3-study initiated according to plan "This quarter, the company went into execution mode with regards to the preparations related to...


01 Oct, 2018, 07:23 BST Presentation at International IgA Nephropathy Network Meeting Highlighting Supportive Post-hoc Analysis of the NEFIGAN Study

Calliditas Therapeutics AB (publ) ("Calliditas") today announced supportive post-hoc results from its clinical Phase 2b study NEFIGAN of the...


25 Sep, 2018, 07:22 BST Post-hoc Results From NEFIGAN Study to be Presented at the International IgA Nephropathy Network Meeting (IIgANN)

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that post-hoc results from its clinical Phase 2b study NEFIGAN will be presented in...